# Annette Bauer-Brandl

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 101 papers | 2,886 citations | 31 h-index | 48 g-index |
| 107 ext. papers | 3,261 ext. citations | 4.6 avg, IF | 5.36 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 101 | Microdialysis and nanofiltration allow to distinguish molecularly dissolved from colloid- associated drug concentrations during biomimetic dissolution testing of supersaturating formulations.. *European Journal of Pharmaceutical Sciences*, **2022**, 106166 | 5.1 | 0 |
| 100 | Raman Imaging as a powerful tool to elucidate chemical processes in a matrix: Medicated chewing gums with nicotine.. *Journal of Pharmaceutical and Biomedical Analysis*, **2021**, 209, 114519 | 3.5 | |
| 99 | Stirred not Shaken! Comparing Agitation Methods for Permeability Studies Using a Novel Type of 96-Well Sandwich-Plates. *Journal of Pharmaceutical Sciences*, **2021**, | 3.9 | 2 |
| 98 | Acute effects of delayed-release hydrolyzed pine nut oil on glucose tolerance, incretins, ghrelin and appetite in healthy humans. *Clinical Nutrition*, **2021**, 40, 2169-2179 | 5.9 | 2 |
| 97 | Do Phospholipids Boost or Attenuate Drug Absorption? In Vitro and In Vivo Evaluation of Mono- and Diacyl Phospholipid-Based Solid Dispersions of Celecoxib. *Journal of Pharmaceutical Sciences*, **2021**, 110, 198-207 | 3.9 | 4 |
| 96 | Enabling formulations of aprepitant: and comparison of nanocrystalline, amorphous and deep eutectic solvent based formulations. *International Journal of Pharmaceutics: X*, **2021**, 3, 100083 | 3.2 | 1 |
| 95 | Drug Permeability Profiling Using the Novel Permeapad 96-Well Plate. *Pharmaceutical Research*, **2020**, 37, 93 | 4.5 | 16 |
| 94 | The influence of liquid intake on the performance of an amorphous solid dispersion in rats. *European Journal of Pharmaceutics and Biopharmaceutics*, **2020**, 152, 296-298 | 5.7 | 3 |
| 93 | Exploring impact of supersaturated lipid-based drug delivery systems of celecoxib on in vitro permeation across Permeapad membrane and in vivo absorption. *European Journal of Pharmaceutical Sciences*, **2020**, 152, 105452 | 5.1 | 8 |
| 92 | Dissolution/permeation with PermeaLoop Experience and IVIVC exemplified by dipyridamole enabling formulations. *European Journal of Pharmaceutical Sciences*, **2020**, 154, 105532 | 5.1 | 9 |
| 91 | Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. *European Journal of Pharmaceutical Sciences*, **2019**, 137, 104967 | 5.1 | 118 |
| 90 | High-Throughput Dissolution/Permeation Screening -A 96-Well Two-Compartment Microplate Approach. *Pharmaceutics*, **2019**, 11, | 6.4 | 13 |
| 89 | Co-existing colloidal phases of human duodenal aspirates: Intraindividual fluctuations and interindividual variability in relation to molecular composition. *Journal of Pharmaceutical and Biomedical Analysis*, **2019**, 170, 22-29 | 3.5 | 10 |
| 88 | A dynamic in vitro permeation study on solid mono- and diacyl-phospholipid dispersions of celecoxib. *European Journal of Pharmaceutical Sciences*, **2019**, 127, 199-207 | 5.1 | 17 |
| 87 | Oromucosal drug delivery: Trends in in-vitro biopharmaceutical assessment of new chemical entities and formulations. *European Journal of Pharmaceutical Sciences*, **2019**, 128, 112-117 | 5.1 | 18 |
| 86 | Drug permeability profiling using cell-free permeation tools: Overview and applications. *European Journal of Pharmaceutical Sciences*, **2018**, 119, 219-233 | 5.1 | 75 |
| 85 | Co-existing colloidal phases in artificial intestinal fluids assessed by AF4/MALLS and DLS: A systematic study into cholate & (lyso-) phospholipid blends, incorporating celecoxib as a model drug. *European Journal of Pharmaceutical Sciences*, **2018**, 120, 61-72 | 5.1 | 10 |

| | | | |
|---|---|---|---|
| 84 | PermeaLoop□a novel in vitro tool for small-scale drug-dissolution/permeation studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2018**, 156, 247-251 | 3.5 | 17 |
| 83 | Evaluation of a dynamic dissolution/permeation model: Mutual influence of dissolution and barrier-flux under non-steady state conditions. *International Journal of Pharmaceutics*, **2017**, 522, 50-57 | 6.5 | 17 |
| 82 | Simultaneous lipolysis/permeation in vitro model, for the estimation of bioavailability of lipid based drug delivery systems. *European Journal of Pharmaceutics and Biopharmaceutics*, **2017**, 117, 300-307 | 5.7 | 39 |
| 81 | Characterization of co-existing colloidal structures in fasted state simulated fluids FaSSIF: A comparative study using AF4/MALLS, DLS and DOSY. *Journal of Pharmaceutical and Biomedical Analysis*, **2017**, 145, 531-536 | 3.5 | 12 |
| 80 | Surfactants enhance recovery of poorly soluble drugs during microdialysis sampling: Implications for in vitro dissolution-/permeation-studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2017**, 145, 586-592 | 3.5 | 6 |
| 79 | Oral bioavailability enhancement through supersaturation: an update and meta-analysis. *Expert Opinion on Drug Delivery*, **2017**, 14, 403-426 | 8 | 54 |
| 78 | A novel microdialysis-dissolution/permeation system for testing oral dosage forms: A proof-of-concept study. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 154-163 | 5.1 | 9 |
| 77 | Dynamic dissolution-/permeation-testing of nano- and microparticle formulations of fenofibrate. *European Journal of Pharmaceutical Sciences*, **2017**, 96, 20-27 | 5.1 | 31 |
| 76 | Use of Permeapad□ for prediction of buccal absorption: A comparison to in vitro, ex vivo and in vivo method. *European Journal of Pharmaceutical Sciences*, **2016**, 93, 399-404 | 5.1 | 17 |
| 75 | Solid Phospholipid Dispersions for Oral Delivery of Poorly Soluble Drugs: Investigation Into Celecoxib Incorporation and Solubility-In Vitro Permeability Enhancement. *Journal of Pharmaceutical Sciences*, **2016**, 105, 1113-23 | 3.9 | 30 |
| 74 | Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release-/transfer-assay. *Journal of Controlled Release* , **2016**, 232, 228-37 | 11.7 | 18 |
| 73 | Cocrystals of the antiandrogenic drug bicalutamide: screening, crystal structures, formation thermodynamics and lattice energies. *CrystEngComm*, **2016**, 18, 4818-4829 | 3.3 | 33 |
| 72 | Permeapad□for investigation of passive drug permeability: The effect of surfactants, co-solvents and simulated intestinal fluids (FaSSIF and FeSSIF). *International Journal of Pharmaceutics*, **2015**, 493, 192-7 | 6.5 | 31 |
| 71 | New biomimetic barrier Permeapad□for efficient investigation of passive permeability of drugs. *European Journal of Pharmaceutical Sciences*, **2015**, 73, 29-34 | 5.1 | 73 |
| 70 | Diversity of felodipine solvates: structure and physicochemical properties. *CrystEngComm*, **2015**, 17, 4089-4097 | 3.3 | 16 |
| 69 | Chitosan based micro- and nanoparticles for colon-targeted delivery of vancomycin prepared by alternative processing methods. *European Journal of Pharmaceutics and Biopharmaceutics*, **2015**, 92, 112-9 | 5.7 | 77 |
| 68 | Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying. *International Journal of Pharmaceutics*, **2015**, 496, 382-91 | 6.5 | 51 |
| 67 | Phospholipid-based solid drug formulations for oral bioavailability enhancement: A meta-analysis. *European Journal of Pharmaceutical Sciences*, **2015**, 80, 89-110 | 5.1 | 27 |

| | | | |
|---|---|---|---|
| 66 | Solid phospholipid nano-particles: investigations into formulation and dissolution properties of griseofulvin. *International Journal of Pharmaceutics*, **2014**, 467, 42-7 | 6.5 | 19 |
| 65 | Cyclodextrin-dextran polymers for the solubilization of poorly soluble drugs. *International Journal of Pharmaceutics*, **2014**, 468, 258-63 | 6.5 | 24 |
| 64 | Polymorphism of felodipine co-crystals with 4,4?-bipyridine. *CrystEngComm*, **2014**, 16, 6603-6611 | 3.3 | 22 |
| 63 | Cocrystal screening of hydroxybenzamides with benzoic acid derivatives: a comparative study of thermal and solution-based methods. *European Journal of Pharmaceutical Sciences*, **2014**, 65, 56-64 | 5.1 | 41 |
| 62 | Single step bottom-up process to generate solid phospholipid nano-particles. *Pharmaceutical Development and Technology*, **2014**, 19, 326-32 | 3.4 | 13 |
| 61 | Crystal architecture and physicochemical properties of felodipine solvates. *CrystEngComm*, **2013**, 15, 6054 | 3.3 | 14 |
| 60 | Cimetidine, C10H16N6S, form C: crystal structure and modelling of polytypes using the superspace approach. *Journal of Applied Crystallography*, **2013**, 46, 99-107 | 3.8 | 13 |
| 59 | On the drug-loading capacity of pectin powder for direct compression. *AAPS PharmSciTech*, **2012**, 13, 601-4 | 3.9 | |
| 58 | A method for simultaneous quantification of phospholipid species by routine 31P NMR. *Journal of Pharmaceutical and Biomedical Analysis*, **2012**, 70, 708-12 | 3.5 | 21 |
| 57 | Overcoming instability and low solubility of new cytostatic compounds: a comparison of two approaches. *European Journal of Pharmaceutics and Biopharmaceutics*, **2012**, 80, 657-62 | 5.7 | 17 |
| 56 | Effect of degree of methoxylation and particle size on compression properties and compactibility of pectin powders. *Pharmaceutical Development and Technology*, **2012**, 17, 333-43 | 3.4 | 6 |
| 55 | Crystallization and Polymorphism of Felodipine. *Crystal Growth and Design*, **2012**, 12, 4022-4030 | 3.5 | 44 |
| 54 | Felodipine-diazabicyclo[2.2.2]octane-water (1/1/1). *Acta Crystallographica Section C: Crystal Structure Communications*, **2012**, 68, o456-8 | | 3 |
| 53 | Quality by design (QbD) approaches for the compression step of tableting. *Expert Opinion on Drug Delivery*, **2011**, 8, 1631-44 | 8 | 17 |
| 52 | A novel method for the investigation of liquid/liquid distribution coefficients and interface permeabilities applied to the water-octanol-drug system. *Pharmaceutical Research*, **2011**, 28, 2140-6 | 4.5 | 12 |
| 51 | Liposomal solubilization of new 3-hydroxy-quinolinone derivatives with promising anticancer activity: a screening method to identify maximum incorporation capacity. *Journal of Liposome Research*, **2011**, 21, 272-8 | 6.1 | 23 |
| 50 | Solubilization of ibuprofen with cyclodextrin derivatives: energetic and structural studies. *Journal of Pharmaceutical and Biomedical Analysis*, **2011**, 55, 446-51 | 3.5 | 50 |
| 49 | Comparative evaluation of the powder and compression properties of various grades and brands of microcrystalline cellulose by multivariate methods. *Pharmaceutical Development and Technology*, **2010**, 15, 394-404 | 3.4 | 21 |

| | | | |
|---|---|---|---|
| 48 | Direct compression behavior of low- and high-methoxylated pectins. *AAPS PharmSciTech*, **2010**, 11, 18-26 | 3.9 | 14 |
| 47 | Evaluation of a rapid approximation method for the elastic recovery of tablets. *Powder Technology*, **2010**, 202, 71-77 | 5.2 | 33 |
| 46 | On the physical interpretation of the initial bending of a Shapiro-Konopicky-Heckel compression profile. *European Journal of Pharmaceutics and Biopharmaceutics*, **2009**, 71, 395-401 | 5.7 | 28 |
| 45 | Application of multivariate methods to compression behavior evaluation of directly compressible materials. *European Journal of Pharmaceutics and Biopharmaceutics*, **2009**, 72, 148-55 | 5.7 | 57 |
| 44 | Multivariate analysis of relationships between material properties, process parameters and tablet tensile strength for alpha-lactose monohydrates. *European Journal of Pharmaceutics and Biopharmaceutics*, **2009**, 73, 424-31 | 5.7 | 35 |
| 43 | Thermodynamic and Structural Aspects of Some Fenamate Molecular Crystals. *Crystal Growth and Design*, **2009**, 9, 3265-3272 | 3.5 | 46 |
| 42 | Characterisation of the Ion Exchange Reaction Between Propranolol-H+ or K+ with Amberlite IRP 69 Resin by Both, Isothermal Titration Calorimetry and (Flame) Photometric Equilibrium Analysis. *Open Drug Delivery Journal*, **2009**, 3, 10-18 | | 3 |
| 41 | Extent and mechanism of solvation and partitioning of isomers of substituted benzoic acids: a thermodynamic study in the solid state and in solution. *Journal of Pharmaceutical Sciences*, **2008**, 97, 3883-96 | 3.9 | 22 |
| 40 | Influence of position and size of substituents on the mechanism of partitioning: a thermodynamic study on acetaminophens, hydroxybenzoic acids, and parabens. *AAPS PharmSciTech*, **2008**, 9, 205-16 | 3.9 | 22 |
| 39 | Development of a melting tablet containing promethazine HCl against motion sickness. *AAPS PharmSciTech*, **2008**, 9, 1006-15 | 3.9 | 18 |
| 38 | Thermodynamic and Structural Aspects of Hydrated and Unhydrated Phases of 4-Hydroxybenzamide. *Crystal Growth and Design*, **2007**, 7, 2643-2648 | 3.5 | 18 |
| 37 | Energetic aspects of diclofenac acid in crystal modifications and in solutions--mechanism of solvation, partitioning and distribution. *Journal of Pharmaceutical Sciences*, **2007**, 96, 1031-42 | 3.9 | 30 |
| 36 | Redetermination of 3-hydroxybenzamide. *Acta Crystallographica Section E: Structure Reports Online*, **2007**, 63, o2359-o2360 | | 1 |
| 35 | 3-(Acetylamino)benzoic acid. *Acta Crystallographica Section E: Structure Reports Online*, **2007**, 63, o2361-o2361 | | 2 |
| 34 | 4-Hydroxybenzamide. *Acta Crystallographica Section E: Structure Reports Online*, **2007**, 63, o2362-o2362 | | 7 |
| 33 | Pyridine-3-carbaldehyde 2-pyridylhydrazone. *Acta Crystallographica Section E: Structure Reports Online*, **2007**, 63, o3042-o3042 | | |
| 32 | Polymorphism of paracetamol. *Journal of Thermal Analysis and Calorimetry*, **2007**, 89, 767-774 | 4.1 | 46 |
| 31 | Thermodynamic properties of flufenamic and niflumic acids--specific and non-specific interactions in solution and in crystal lattices, mechanism of solvation, partitioning and distribution. *Journal of Pharmaceutical and Biomedical Analysis*, **2007**, 45, 679-87 | 3.5 | 31 |

| | | | |
|---|---|---|---|
| 30 | pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. *European Journal of Pharmaceutics and Biopharmaceutics*, **2007**, 65, 78-84 | 5.7 | 57 |
| 29 | Thermodynamic study of sublimation, solubility, solvation, and distribution processes of atenolol and pindolol. *Molecular Pharmaceutics*, **2007**, 4, 929-35 | 5.6 | 20 |
| 28 | The difference between partitioning and distribution from a thermodynamic point of view: NSAIDs as an example. *European Journal of Pharmaceutical Sciences*, **2006**, 27, 150-7 | 5.1 | 21 |
| 27 | Towards an understanding of the molecular mechanism of solvation of drug molecules: a thermodynamic approach by crystal lattice energy, sublimation, and solubility exemplified by hydroxybenzoic acids. *Journal of Pharmaceutical Sciences*, **2006**, 95, 1448-58 | 3.9 | 24 |
| 26 | Towards an understanding of the molecular mechanism of solvation of drug molecules: a thermodynamic approach by crystal lattice energy, sublimation, and solubility exemplified by paracetamol, acetanilide, and phenacetin. *Journal of Pharmaceutical Sciences*, **2006**, 95, 2158-69 | 3.9 | 67 |
| 25 | Redetermination of p-ethoxyacetanilide (phenacetin). *Acta Crystallographica Section E: Structure Reports Online*, **2006**, 62, o2712-o2713 | | 3 |
| 24 | Redetermination and H-atom refinement of (S)-(+)-ibuprofen. Corrigendum.. *Acta Crystallographica Section E: Structure Reports Online*, **2006**, 62, e17-e18 | | 4 |
| 23 | N-(3-Hydroxyphenyl)acetamide. *Acta Crystallographica Section E: Structure Reports Online*, **2006**, 62, o3627-o3628 | | 3 |
| 22 | Isothermal titration calorimetry (ITC) method to study drug/ion exchanger interaction. *Journal of Thermal Analysis and Calorimetry*, **2006**, 83, 309-312 | 4.1 | 5 |
| 21 | Thermodynamics of solubility, sublimation and solvation processes of parabens. *European Journal of Pharmaceutical Sciences*, **2005**, 24, 25-33 | 5.1 | 49 |
| 20 | Solvation of drugs as a key for understanding partitioning and passive transport exemplified by NSAIDs. *Current Drug Delivery*, **2004**, 1, 213-26 | 3.2 | 50 |
| 19 | Solvation and hydration characteristics of ibuprofen and acetylsalicylic acid. *AAPS PharmSci*, **2004**, 6, E3 | | 41 |
| 18 | Thermodynamics of sublimation, crystal lattice energies, and crystal structures of racemates and enantiomers: (+)- and (+/-)-ibuprofen. *Journal of Pharmaceutical Sciences*, **2004**, 93, 654-66 | 3.9 | 74 |
| 17 | Effect of hydroxypropyl-beta-cyclodextrin-complexation and pH on solubility of camptothecin. *International Journal of Pharmaceutics*, **2004**, 284, 61-8 | 6.5 | 45 |
| 16 | Thermodynamics of solutions III: comparison of the solvation of (+)-naproxen with other NSAIDs. *European Journal of Pharmaceutics and Biopharmaceutics*, **2004**, 57, 411-20 | 5.7 | 200 |
| 15 | Solvates with anomalous low melting points. *Journal of Thermal Analysis and Calorimetry*, **2003**, 73, 715-725 | 4.1 | 3 |
| 14 | Thermodynamics of solutions I: benzoic acid and acetylsalicylic acid as models for drug substances and the prediction of solubility. *Pharmaceutical Research*, **2003**, 20, 471-8 | 4.5 | 32 |
| 13 | Thermodynamics of solutions. II. Flurbiprofen and diflunisal as models for studying solvation of drug substances. *European Journal of Pharmaceutical Sciences*, **2003**, 19, 423-32 | 5.1 | 128 |

| | | | |
|---|---|---|---|
| 12 | Driving forces and the influence of the buffer composition on the complexation reaction between ibuprofen and HPCD. *European Journal of Pharmaceutical Sciences*, **2003**, 20, 197-200 | 5.1 | 26 |
| 11 | Thermodynamics of solutions IV: Solvation of ketoprofen in comparison with other NSAIDs. *Journal of Pharmaceutical Sciences*, **2003**, 92, 2502-11 | 3.9 | 32 |
| 10 | Note on the measurement of flowability according to the European Pharmacopoeia. *International Journal of Pharmaceutics*, **2003**, 257, 301-4 | 6.5 | 48 |
| 9 | Redetermination and H-atom refinement of (S)-(+)-ibuprofen. *Acta Crystallographica Section E: Structure Reports Online*, **2003**, 59, o1357-o1358 | | 15 |
| 8 | Interrelation between thermochemical and structural data of polymorphs exemplified by diflunisal. *Journal of Pharmaceutical Sciences*, **2002**, 91, 1036-45 | 3.9 | 19 |
| 7 | The methanol hemisolvate of amiloride hydrochloride. *Acta Crystallographica Section C: Crystal Structure Communications*, **2001**, 57, 1217-9 | | 3 |
| 6 | Diflunisal–hexane (4/1). *Acta Crystallographica Section E: Structure Reports Online*, **2001**, 57, o604-o606 | | 5 |
| 5 | The Melting Process of Acetylsalicylic Acid Single Crystals **2001**, 63, 653-661 | | 18 |
| 4 | The Polymorphism of Glycine. Thermochemical and structural aspects. *Magyar Aprólad Közlemények*, **2001**, 66, 699-715 | 0 | 171 |
| 3 | Properties of fujicalin, a new modified anhydrous dibasic calcium phosphate for direct compression: comparison with dicalcium phosphate dihydrate. *Drug Development and Industrial Pharmacy*, **2001**, 27, 789-801 | 3.6 | 32 |
| 2 | Influence of tableting forces and lubricant concentration on the adhesion strength in complex layer tablets. *Drug Development and Industrial Pharmacy*, **2000**, 26, 745-54 | 3.6 | 26 |
| 1 | On the accuracy of a new displacement instrumentation for rotary tablet presses. *Drug Development and Industrial Pharmacy*, **1999**, 25, 117-30 | 3.6 | 21 |